MSB 7.69% $1.19 mesoblast limited

Ann: Mesoblast Update on COVID-19 ARDS Trial, page-340

  1. 144 Posts.
    lightbulb Created with Sketch. 44
    they ended the trial because it isn't working. The stats are not showing it is having the impact they conservatively estimated. Its over for ARDS. Next is Novartis ending its license.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.